SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending following a significant analyst upgrade and intense community anticipation ahead of the upcoming AAD conference in Denver, where long-term Phase 3 data for sonelokimab is expected to be presented. Investors are closely monitoring potential acquisition interest from major pharmaceutical players while debating whether clinical outcomes will confirm the therapy as best-in-class.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is currently trending as investors weigh an upcoming earnings report against significant concerns regarding execution gaps in China, intensifying domestic competition, and a persistent multi-month downtrend. The community is sharply divided, with bulls pointing to historical support levels and insider buying by key executives as a sign of a potential turnaround, while bears highlight consistent technical weakness and structural risks.

Roma Green Finance Ltd. is a holding company, which engages in the provision of environmental, social and governance, sustainability, and climate change related advisory services through its subsidiaries. Its services include corporate and risk advisory, sustainability strategy services, climate risk advisory, ESG reporting services, and sustainable finance. The company was founded in 2018 and is headquartered in Hong Kong.

Roma Green Finance Ltd - Ordinary Shares - Class A

Roma Green Finance Ltd

Roma Green Finance is seeing increased attention as investors track its recent momentum, with the community actively debating whether the stock is primed for a breakout or remains a volatile candidate for a pump-and-dump. Traders are closely monitoring key support levels and volume patterns, frequently referencing its history of sharp price swings and the speculative potential often associated with small-cap stocks in this sector.

Fermi, Inc. engages in the development of energy infrastructure. It intends to develop an energy and data center development campus to support the needs of to-be-built AI infrastructure. The company was founded by Rick Perry, Toby Neugebauer and Griffin Perry on January 10, 2025 and is headquartered in Amrillo, TX.

Fermi Inc

Fermi LLC

Fermi LLC is trending as investors closely monitor volatility surrounding the company's ambitious 17GW infrastructure project, with active discussions focused on potential tenant announcements, legislative updates, and significant short-term call option activity. Community sentiment remains polarized, as stakeholders weigh the project's long-term potential for powering AI data centers against the risks associated with construction timelines, financing, and recent legal developments.

Viridian Therapeutics, Inc. is a biopharmaceutical company that develops medicines for autoimmune and rare diseases. It uses antibody discovery and protein engineering to create new therapies. The company is advancing late-stage IGF-1R therapies for thyroid eye disease (TED) and developing a potential TSHR-targeted treatment for TED and Graves’ disease. In addition, it is developing FcRn inhibitors, including VRDN-006 and VRDN-008, for multiple autoimmune diseases. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Waltham, MA.

Viridian Therapeutics Inc

Viridian Therapeutics is facing increased attention as investors closely monitor its pipeline of thyroid eye disease treatments, particularly following a series of analyst updates and the company's progress toward key clinical milestones. Community discussion remains centered on the potential for its therapies to offer a competitive edge in the market, while shareholders navigate broader volatility in the biotech sector.

Sigma Lithium Corp. engages in the producing of a lithium property. It focuses its project in Minas Gerais. The firm also plans to build a world-class commercial-scale lithium concentration plant. The company was founded on June 8, 2011 and is headquartered in Sao Paulo, Brazil.

Sigma Lithium Corporation

Sigma Lithium is generating significant market interest as investors closely monitor reports of a major spodumene supply deficit and rising lithium futures. While bullish community sentiment is fueled by expectations of strong 2026 growth and potential production capacity increases, the stock remains a battlefield between retail investors anticipating a breakout and short sellers targeting concerns over operational timelines and liquidity.

Solana Street Bets is not just a memecoin; it's a symbol of creativity, humor, and the power of a united community. Inspired by the infamous /wallstreetbets subreddit. Solana Street Bets is here to put respect on the Wall St originated memes in the industry. Solana Street Bets is a decentralized Solana meme coin inspired by the infamous /wallstreetbets subreddit.

SatoshiStreetBets

SatoshiStreetBets ($SSB) is currently trending as a highly speculative memecoin play on the Solana network, with community members aggressively lobbying for official chart visibility on major financial tracking platforms. Sentiment is sharply divided between believers pushing for long-term utility and massive growth, and vocal critics who characterize the project as a poorly managed scam or rug pull.

Sable Offshore Corp. engages in offshore oil and gas field operations. It focuses on developing the prolific Santa Ynez Unit in federal waters offshore California. The company was founded by James C. Flores on October 16, 2020 and is headquartered in Houston, TX.

Sable Offshore Corp.

Sable Offshore is trending as traders react to reports that the Trump administration plans to invoke the Defense Production Act to bypass California state regulations and expedite the restart of the company's oil pipeline system. The community is actively discussing the potential for a significant short squeeze, given high short interest levels and the stock's role as a strategic domestic energy asset amid broader geopolitical supply concerns.

Americas Gold & Silver Corp. engages in the acquisition, exploration, development, and exploration of mineral resource properties. It operates through the following segments: Cosalá Operations, Galena Complex, Relief Canyon, and Corporate and Other. The Cosalá Operations segment operates in Mexico. The Galena Complex and Relief Canyon segments focuses on the United States. The company was founded by Peter Jude Hawley on May 12, 1998 and is headquartered in Toronto, Canada.

Americas Gold and Silver Corp

Americas Gold and Silver Corporation

Americas Gold and Silver is seeing significant community attention driven by a combination of surging silver and antimony prices, alongside the acquisition of the Crescent Mine. Investors are actively debating the stock's potential for a major re-rating as they monitor physical silver supply tightness, the companys internal operational growth, and the broader impact of critical mineral policies on domestic production.

Sysco Corp. engages in the selling, marketing, and distribution of food products to restaurants, healthcare and educational facilities, and lodging establishments. It operates through the following segments: U.S. Foodservice Operations, International Foodservice Operations, SYGMA, and Other. The U.S. Foodservice Operations segment consists of U.S. Broadline operations, custom-cut meat and seafood companies, FreshPoint, and European Imports. The International Foodservice Operations segment includes operations outside of the United States which distribute a full line of food products and a wide variety of non-food products. The SYGMA segment represents U.S. customized distribution operations serving quick-service chain restaurant customer locations. The Other segment covers hotel supply operations. The company was founded by John F. Baugh in 1969 and is headquartered in Houston, TX.

Sysco Corp.

Sysco is trending as investors weigh strong operational performance and market leadership against ongoing macroeconomic headwinds and a tight labor market. The community is actively debating the company's defensive status, dividend reliability, and the potential impact of its strategic investments in supply chain technology and fleet electrification.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Agenus (NASDAQ:AGEN) Downgraded to "Hold" Rating by Wall Street Zen

Wall Street Zen cut shares of Agenus from a "buy" rating to a "hold" rating in a research note on Sunday...

Agenus Inc. (NASDAQ:AGEN) Given Consensus Rating of "Hold" by Brokerages

Agenus Inc. (NASDAQ:AGEN - Get Free Report) has been assigned a consensus recommendation of "Hold" from the five brokerages that are covering the company, MarketBeat Ratings reports. One research...

Agenus to Host March 2026 Stakeholder Webcast Harnessing the Immune System to Advance BOT + BAL Across Tumor Types and Expand Patient Access

Agenus Inc. (Agenus) (Nasdaq: AGEN), a leader in immuno-oncology, today announced it will host its March Stakeholder Webcast focused on continued progress of its botensilimab and balstilimab (BOT+BAL) immunotherapy program and will provide an update on the Companys patient access programs...

Agenus (NASDAQ:AGEN) Rating Increased to Buy at Wall Street Zen

Wall Street Zen raised shares of Agenus from a "hold" rating to a "buy" rating in a research note on Saturday...

Research Analysts Issue Forecasts for Agenus Q1 Earnings

Agenus Inc. (NASDAQ:AGEN - Free Report) - Analysts at HC Wainwright cut their Q1 2026 earnings per share (EPS) estimates for Agenus in a research note issued on Monday, March 16th. HC Wainwright...

Agenus Announces Upcoming AACR 2026 Presentation Evaluating Botensilimab Plus Balstilimab in First-Line MSS Metastatic Colorectal Cancer

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced that preliminary results from an investigator-sponsored study evaluating botensilimab (BOT) in combination with balstilimab...

Agenus (NASDAQ:AGEN) Issues Quarterly Earnings Results

Agenus (NASDAQ:AGEN - Get Free Report) issued its earnings results on Monday. The biotechnology company reported $0.56 earnings per share (EPS) for the quarter, beating the consensus estimate of...

Agenus (AGEN) Q4 Earnings and Revenues Surpass Estimates

Agenus (AGEN) delivered earnings and revenue surprises of +144.27% and +17.54%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Agenus Reports 2025 Results; BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally with Initial Revenues Recognized

Agenus Inc. (Nasdaq: AGEN) today reported financial results for the fourth quarter and full year ended December 31, 2025, highlighting progress for the botensilimab (BOT) plus balstilimab (BAL...

CervoMed Inc. (CRVO) Reports Q4 Loss, Lags Revenue Estimates

CERVOMED INC (CRVO) delivered earnings and revenue surprises of -10.93% and -98.06%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Agenus, Inc. is a clinical-stage company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes Balstilimab, Zalifrelimab, AGEN1181, AGEN1327, AGEN2373, AGENt-797 and AGEN1777. The company was founded by Garo H. Armen and Pramod K. Srivastava on March 31, 1994 and is headquartered in Lexington, MA.

Agenus Inc

Peloswing

JFDI

ACInvestorBlog

GPaisa

A pillar of the Stocktwits ecosystem. This award recognizes the member who fosters connection, shares invaluable insights, and elevates the daily discussion to empower their fellow traders, on-platform.

AGEN
Agenus Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest AGEN News

AGENAgenus Inc